Posted by Michael Wonder on 16 May 2024
Axogen initiates rolling submission of biologics license application to US FDA for Avance Nerve Graft
16 May 2024 - Axogen is pleased to announce that it has initiated the rolling submission process with the US FDA for a biologics license application for licensure of Avance Nerve Graft on 15 May 2024.
The initial submission to the US FDA includes the complete non-clinical data package for the biologics license application.
